ArticleChild and adolescent psychiatry and mental health2008
A three-country comparison of psychotropic medication prevalence in youth.
Article in Child and adolescent psychiatry and mental health, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 72 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
72 citing papers in PubMed, 211 citations in OpenAlex.
- Trial
- Feasibility of a Stepped-Care Intervention for Those at Clinical High Risk for Psychosis in the United States.Early intervention in psychiatry · 2026Article
- Concussion history is associated with poor sleep quality in adolescent athletes: a cross-sectional study.Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine · 2025Article
- Prevalence of use of on-label and off-label psychotropics in the Greek pediatric population.Frontiers in pharmacology · 2024Article
- Article
- Selective serotonin reuptake inhibitors and suicidality in children and young adults: analyses of pharmacovigilance databases.BMC pharmacology & toxicology · 2023Article
- Pediatric Psychotropic Polypharmacy: An Evaluation of the Correlates and Prevalence Across Assessment Cycles in the National Health and Nutrition Examination Survey.Journal of child and adolescent psychopharmacology · 2022Article
- Trends in the Prevalence of Chronic Medication Use Among Children in Israel Between 2010 and 2019: Protocol for a Retrospective Cohort Study.JMIR research protocols · 2022Article
- Sleep pattern and predictors of daily versus as-needed hypnotics use in middle-aged and older adults with insomnia.BMC primary care · 2022Article
- Comparison of Rates of Type 2 Diabetes in Adults and Children Treated With Anticonvulsant Mood Stabilizers.JAMA network open · 2022Observational
- Trends in the utilization of psychotropic medications in China from 2018 to 2021.Frontiers in pharmacology · 2022Article
- Psychotropic medicine consumption in 65 countries and regions, 2008-19: a longitudinal study.The lancet. Psychiatry · 2021Article
- The Use of Antidepressants, Antipsychotics, and Stimulants in Youth Residential Care.Journal of child and adolescent psychopharmacology · 2021Article
- Use of Antidepressants among Patients Diagnosed with Depression: A Scoping Review.BioMed research international · 2021Article
- Effectiveness of mandatory peer review to reduce antipsychotic prescriptions for Medicaid-insured children.Health services research · 2020Observational
- The Use of Sleep Medication in Youth Residential Care.Journal of child and adolescent psychopharmacology · 2020Article
- 'Use of antipsychotics in children and adolescents: a picture from the ARITMO population-based European cohort study'.Epidemiology and psychiatric sciences · 2020Article
- Prescriptions for Alpha Agonists and Antipsychotics in Children and Youth with Tic Disorders: A Pharmacoepidemiologic Study.Tremor and other hyperkinetic movements (New York, N.Y.) · 2019Article
- Benzodiazepine prescribing for children, adolescents, and young adults from 2006 through 2013: A total population register-linkage study.PLoS medicine · 2018Article
- Clinical factors associated with decision to recommend methylphenidate treatment for children with ADHD in France.European child & adolescent psychiatry · 2018Article
12 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 5 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe study aims to compare cross-national prevalence of psychotropic medication use in youth.
methodsA population-based analysis of psychotropic medication use based on administrative claims data for the year 2000 was undertaken for insured enrollees from 3 countries in relation to age group (0-4, 5-9, 10-14, and 15-19), gender, drug subclass pattern and concomitant use. The data include insured youth aged 0-19 in the year 2000 from the Netherlands (n = 110,944), Germany (n = 356,520) and the United States (n = 127,157).
resultsThe annual prevalence of any psychotropic medication in youth was significantly greater in the US (6.7%) than in the Netherlands (2.9%) and in Germany (2.0%). Antidepressant and stimulant prevalence were 3 or more times greater in the US than in the Netherlands and Germany, while antipsychotic prevalence was 1.5-2.2 times greater. The atypical antipsychotic subclass represented only 5% of antipsychotic use in Germany, but 48% in the Netherlands and 66% in the US. The less commonly used drugs e.g. alpha agonists, lithium and antiparkinsonian agents generally followed the ranking of US>Dutch>German youth with very rare (less than 0.05%) use in Dutch and German youth. Though rarely used, anxiolytics were twice as common in Dutch as in US and German youth. Prescription hypnotics were half as common as anxiolytics in Dutch and US youth and were very uncommon in German youth. Concomitant drug use applied to 19.2% of US youth which was more than double the Dutch use and three times that of German youth.
conclusionProminent differences in psychotropic medication treatment patterns exist between youth in the US and Western Europe and within Western Europe. Differences in policies regarding direct to consumer drug advertising, government regulatory restrictions, reimbursement policies, diagnostic classification systems, and cultural beliefs regarding the role of medication for emotional and behavioral treatment are likely to account for these differences.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.